Online inquiry

IVTScrip™ mRNA-Anti-TLR2, OPN-305(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12851MR)

This product GTTS-WQ12851MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets TLR2 gene. The antibody can be applied in Myelodysplastic syndromes (MDS) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001318787.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7097
UniProt ID O60603
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TLR2, OPN-305(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ12851MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14202MR IVTScrip™ mRNA-Anti-IL17A, RG4934(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA RG4934
GTTS-WQ13475MR IVTScrip™ mRNA-Anti-IgG-Fc, PRTX-100(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA PRTX-100
GTTS-WQ4453MR IVTScrip™ mRNA-Anti-SLAMF7, BMS-901608(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BMS-901608
GTTS-WQ7253MR IVTScrip™ mRNA-Anti-STAB1, FP-1302(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA FP-1302
GTTS-WQ9894MR IVTScrip™ mRNA-Anti-pcrV, KB001-A(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA KB001-A
GTTS-WQ2715MR IVTScrip™ mRNA-Anti-CD19&CD3E, AMG103(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA AMG103
GTTS-WQ1165MR IVTScrip™ mRNA-Anti-TNF, ABP 501(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ABP 501
GTTS-WQ7509MR IVTScrip™ mRNA-Anti-HBV, GC-1102(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA GC-1102
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW